<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cetuximab is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor(EGFR) </plain></SENT>
<SENT sid="1" pm="."><plain>This targeting agent was permitted for use with unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue express positive EGFR immunohistochemical staining in Japan from September 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>Cetuximab was certified its beneficial response to KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients while EGFR expression was not a proof of response </plain></SENT>
<SENT sid="3" pm="."><plain>That, however, is not the only predictive factor, but <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> as an adverse event is considered to be a good predictive factor </plain></SENT>
<SENT sid="4" pm="."><plain>We retrospectively evaluated <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> to determine whether or not its appearance would be the predictive factor of cetuximab response to 66 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients in our institution </plain></SENT>
<SENT sid="5" pm="."><plain>The result should that 93 </plain></SENT>
<SENT sid="6" pm="."><plain>8% of patients who experienced severe skin toxity(grade 2-3)responded well(SD, PR and CR)to cetuximab </plain></SENT>
</text></document>